Novar3/Incyte launches jakafi Phase II Covid-19 Phase III clinical trial

, Novart and Incyte announced that they will launch the second Phase III clinical trial of JAK inhibitor Jakafi (ruxolitinib) for COVID-19 to evaluate the safety and effectiveness of Jakafi Joint Standard Care (SoC) in patients with acute respiratory distress syndrome (ARDS) COVID-19 that requires mechanical aeration.Jakafi has long been involved in the fight against COVID-19 as a treatment for severe respiratory immune responses. In early April, Novart and Incyte launched a global, randomized, double-blind, placebo-controlled Phase III clinical trial called Ruxcovid, which evaluated the efficacy and safety of cytokine storms in patients with Jakafi combined with SoC to treat COVID-19. Cytokine storms are a severe immune overreact, which can lead to life-threatening respiratory complications in patients with COVID-19.Jakafi is an innovative oral Janus kinase 1 and 2 (JAK1/JAK2) inhibitor approved by the FDA in 2011 for the treatment of bone marrow fibrosis, followed by the approval of true erythroid encephalopathy and acute graft anti-host disease (GVHD). Based on preliminary reports from preclinical evidence and independent studies, as well as Jakafi's safety in treating diseases such as GVHD, Novartic and Incyte believe That Jakafi has the potential to allow COVID-19 patients to recover faster and reduce the need for intensive care and mechanical breathing.In addition, Roche's IL-6 inhibitors Actemra and Sanofi/Regenerative IL-6 inhibitors Kevzara have also been tested in Phase 3 clinical trials in patients with severe COVID-19.Given the urgency of the COVID-19 pandemic, Incyte also launched the Emergency Expanded Use Program (EAP) in the United States, which allows eligible patients with severe COVID-19-related cytokine storms to receive Jakafi in studies of the condition. (
Sina Pharmaceutical News
)